Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Cloud Gaming for Travelers Outlook 2026-2030 - Featuring Profiles of Microsoft, NVIDIA, and Sony Interactive EntertainmentCompanies: MicrosoftNvidiaSony Group5G, edge computing and rising travel are driving opportunities in low-latency, cross-device subscriptions, adaptive streaming and in-vehicle cloud gaming.
- Fosun International Delivers 160.3% YoY Profit Growth in 1H2026Companies: Fosun International LimitedOn the evening of 27 August, Fosun International announced its 2026 interim results. During the Reporting Period, its total revenue reached RMB86.96 billion; profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; overseas revenue reached RMB49.16 billion, with its share of total revenue rising to 56.5%; total debt to total capital ratio decreased to 55.7%. These figures show that Fosun’s results fall in the upper-middle range of the Company’s profit alert (profit attributable to owners of the parent is expected to range from approximately RMB1.5 billion to RMB1.8 billion, representing a year-on-year increase of approximately 127% to 172%) issued on 29 July. This marks Fosun’s return to a growth trajectory following the completion of a systematic realignment of “repairing the roof on a sunny day”. Over the past few years, Fosun has taken a rather unconventional path. Since 2022, in response to the severe market disruption caused by the pandemic, the Company has advanced its business streamlining and core business-focused strategy, divesting assets and businesses and generating cumulative cash proceeds of approximately RMB75 billion. In March 2026, pursuant to the principle of prudence, Fosun made one-off, non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments. The move drew considerable market attention at the time. At the Company’s 2025 annual results presentation at the end of March, Guo Guangchang, Chairman of Fosun International, explained, “This is about ‘repairing the roof on a sunny day’, allowing Fosun to focus its resources and efforts more effectively on core, high-growth areas.” The market has now responded to Fosun’s “repairing the roof on a sunny day” initiative. From the announcement of profit alert in early March to 25 August, before its interim results announcement, Fosun’s share price rose sharply from HKD3.6 to HKD5.41, representing an increase of more than 50%. The market has gradually recognized and priced in the Group’s “risk clearance” efforts. More importantly, the earnings growth driven by the Group’s businesses has begun to materialize. At the 2026 interim results presentation held in Hong Kong on 28 August, Guo Guangchang said: “The strong results recovery we delivered in the first half of the year reflects the outcome of the strategic adjustments we have made over the past few years. Our ‘repairing the roof on a sunny day’ strategy has paid off, allowing us to put historical burdens behind us. These results mark the beginning of Fosun’s continued progress along a trajectory of steady growth.” Solid Core Businesses, with Pharmaceuticals and Insurance Posting Strong Results First, let us look at Fosun’s core businesses. In the first half of 2026, its four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment — generated a total revenue of RMB63.88 billion, accounting for 73.5% of the Group’s total revenue, further demonstrating the results of its core business-focused strategy. Among them, the pharmaceutical and insurance segments delivered particularly strong performance. In the first half of the year, Fosun Pharma achieved operating revenue of RMB20.377 billion. Revenue from innovative drugs recorded a year-on-year increase of 13.84%, with their contribution to pharmaceutical business revenue rising to 33.35%, establishing innovative drugs as a key growth driver. Its innovative biopharmaceutical platform, Henlius, reported revenue of RMB3.5882 billion, representing a year-on-year increase of 27.3%, while net profit amounted to RMB430.4 million, up 10.3% year-on-year, sustaining growth momentum in revenue and profit. Commercialization of innovative drugs continued to gain traction. During the Reporting Period, Fosun Pharma had a total of 20 indications of 7 innovative drugs approved for launch both domestically and overseas. With their revenue share on a steady rise, innovative drugs have become the main growth engine driving the pharmaceutical business forward. The insurance segment delivered a stellar performance, with Fosun’s domestic and overseas insurance companies all posting broad-based improvements. Fidelidade’s overall market share in Portugal reached 30.1%, and its international business accounted for 26.7% of its consolidated total business. In the first half of the year, Fidelidade recorded net profit attributable to owners of the parent of EUR165 million, up 23.8% year-on-year, maintaining steady growth. In Chinese mainland, Pramerica Fosun Life Insurance recorded gross written premiums of RMB8.38 billion in the first half of 2026, up 52.2% year-on-year. Net profit reached RMB780 million, representing a year-on-year increase of 270% and exceeding its net profit for the full year of 2025. Fosun United Health Insurance reported a 36.2% year-on-year increase in revenue and net profit of RMB572 million. Peak Reinsurance’s reinsurance revenue and gross written premiums increased by 25% and 11.8% year-on- year, respectively, while net profit after tax reached USD89.70 million. In April 2026, Moody’s upgraded Peak Re’s rating from Baa1 to A3, with a “stable” outlook. Guo Guangchang said at the results presentation: “Integrating our insurance business with industries in which we have established competitive advantages has been a strategic priority for Fosun for over three decades — a critical linkage we have long sought to unlock. I believe we have now achieved it. This integration will significantly strengthen our industrial operational capabilities and future profitability, providing sustained momentum for Fosun’s development.” “Successfully navigating another cycle” is how the market has described Fosun’s latest round of adjustments. A closer look reveals how Fosun has successfully navigated the cycle. On the one hand, the Group has continued to streamline its business to generate cash proceeds. In the first half of the year, the Group generated proceeds equivalent to more than RMB12.0 billion from the divestment of non-strategic and non-core assets. Its total debt to total capital ratio was reduced to 55.7%, while its cash, bank balances and term deposits amounted to RMB61.214 billion. On the other hand, the innovation and globalization strategy that the Group has been pursuing for years has entered a value-realization phase, serving as the core engine driving profit recovery. Integrated Innovation Strategy Bears Fruit Since innovative drugs took off in the domestic market in 2025, Fosun has repeatedly broken into the spotlight, with multiple innovative drug business development (BD) drawing significant market attention. In fact, as the saying goes, “One minute on stage takes ten years of hard work off stage”. This series of innovation achievements is the result of Fosun’s forward-looking innovation strategy established nearly two decades ago. Notably, for more than a decade, Fosun has built a globally integrated innovation system across its core business areas, combining “independent R&D + investment incubation + ecosystem collaboration”, and has consistently made substantial investments in technology innovation. In the first half of this year alone, investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. In the first half of this year, Fosun saw a series of innovations come to fruition. HANSIZHUANG, independently developed by Henlius, received approval from the National Medical Products Administration (NMPA) for its perioperative indication in gastric cancer, pioneering a postoperative “chemo-sparing” regimen and making it the world’s first and only anti-PD-1 monoclonal antibody approved for this indication. Its core pipeline asset, HLX43, as a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC, has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC), with over 1,500 patients enrolled globally. To date, Henlius has 10 products approved in over 60 countries and regions, and has benefited over 1.1 million patients. In addition, FUMAINING (luvoxmetinib tablets), independently developed by Fosun Pharma, was approved for the treatment of paediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), continuing to fill the gap in the treatment of rare diseases. In terms of neurodegenerative diseases, Fosun Pharma expanded its global collaboration with AriBio on AR1001, extending its rights to develop and commercialize the product to key markets including the U.S., Europe and Japan. Meanwhile, post-marketing confirmatory clinical trials for sodium oligomannate capsules have progressed steadily, with more than 1,000 patients enrolled as of 31 July 2026. In addition, HT001, an oral NLRP3 inhibitor for the treatment of Parkinson’s disease in-licensed by Hengtai Bio, an investee and incubated company of Fosun Pharma, commenced its Phase I clinical trial in Australia. Fosun’s innovation achievements demonstrate the forward-looking nature of its innovation strategy and its ability to identify the right opportunities in R&D. As Guo Guangchang remarked at the results presentation, through years of effort, Fosun has built globally integrated innovation capabilities rooted in China. This distinctive strength of Fosun is expected to create greater value for all in the years ahead. “Fosun has never pursued innovation behind closed doors. Instead, we leverage our resource-integration capabilities and a global perspective to drive smart innovation, bringing together the best technologies, teams and supply chains from around the world to solve real problems. This is how we unlock vast market potential,” said Guo Guangchang. Unlocking Value through Global Operations Globalization has been another forward-looking strategic move for Fosun. Since its listing in Hong Kong in 2007, when many Chinese companies were still focused primarily on their domestic markets, Fosun had already begun expanding overseas ahead of its peers. Nearly two decades later, as a growing number of Chinese companies embrace the view that they must go global or risk being left behind, and seek to capture overseas markets by taking their products overseas, Fosun has already established a profound business presence in more than 40 countries and regions. With local teams operating overseas, it has successfully operated a number of companies within the Fosun ecosystem. “Global operations” have become a defining feature of Fosun’s globalization strategy and a core engine underpinning the development of its businesses. Guo Guangchang said at the interim results presentation that Fosun continues to strengthen its global operational capabilities. On the one hand, it is helping Chinese products and services enter overseas markets. On the other hand, it is introducing high-quality products and services from around the world into China. Drawing on the global resource-mobilization capabilities it has built over the years, Fosun is able to identify high-quality projects and technologies worldwide and rapidly mobilize the resources needed to advance them. In the first half of 2026, Fosun’s overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue, up 3 percentage points as compared to the same period of 2025 and marking a record high in the proportion of overseas revenue. In the field of pharmaceuticals and healthcare, Fosun made substantial progress in the global expansion of innovative drugs and commercial business development. Henlius’ HANSIZHUANG was approved for three new indications in the European Union (EU), while HLX11 (pertuzumab injection) was approved in the EU and HLX14 (denosumab injection) was approved in Canada. At the beginning of 2026, Fosun Pharma entered into a strategic partnership with Eisai for HANSIZHUANG, with an aggregate potential consideration exceeding USD300 million, underscoring how the global value of Chinese innovative drugs is being repriced by international markets. In the first half of the year, Yuyuan generated revenue of RMB532 million in Hong Kong SAR and Macau SAR in the first half of 2026, representing a year-on-year increase of 285.83%, while revenue from the Japanese market reached RMB306 million, representing a year-on-year increase of 6.09%. Laomiao has 15 stores in Hong Kong SAR, Macau SAR, overseas markets and duty-free channels. Club Med has also continued to expand its global footprint, with Club Med Urban Oasis Hangzhou Longwu already open and Club Med South Africa Beach & Safari now in soft opening. Leveraging Fosun’s global ecosystem, Fidelidade in the insurance segment has expanded its business from Portugal to Portuguese-speaking countries and markets across Europe, Latin America, and Africa. Its international business now accounts for 26.7% of its consolidated total business, with continued growth in Portuguese-speaking countries. Meanwhile, Peak Reinsurance has maintained steady growth thanks to its global business footprint. The guiding principle behind Fosun’s globalization strategy is “Combining Global Resources with China’s Capabilities”, deeply integrating China’s manufacturing capabilities, service capabilities, and innovation dividends, with global markets. Starting with leveraging China’s growth momentum to establish its business presence, and progressing to a two-way engagement of “mutual empowerment between China and the world”, Fosun has now entered the 3.0 phase of “global organization + local operations”. In this phase, Fosun “truly operates with a global perspective”, having developed the ability to foster cross-regional, cross-cultural, and cross-organizational synergies within its business ecosystem and support the continued growth of its overseas revenue. At the interim results presentation held on 28 August, Guo Guangchang said: “Fosun’s future development goal is to ‘spur the horse to full speed’. We have already positioned ourselves on a trajectory of steady growth. Going forward, we will continue to advance innovation-driven and global development in industries where we have established competitive advantages, building on our momentum and accelerating further.”
- Redion Holiday Barometer 2026: Singapore Sets a Global Benchmark for the Most Insured Travelers as Expectations for Travel Support RiseSingapore has emerged as the world’s most mature travel protection market, with 86% of travelers covered by travel insurance when they travel, the highest rate recorded globally according to the latest Holiday Barometer 2026 report by Redion (formerly Europ Assistance) and Ipsos. Alongside strong risk awareness among Singaporeans, the findings highlight growing expectations for comprehensive protection for a broader scope of travel risks, with real-time assistance and seamless digital support increasingly viewed as essential elements of the travel journey. As one of the region's most active outbound travel markets with frequent, high-spending travelers and digitally engaged consumers, Singapore offers a glimpse into how traveler expectations are evolving amid growing awareness of global risks. The increasing demand for reassurance through travel protection and assistance is posing a challenge for insurers and travel providers beyond driving insurance penetration towards delivering broader protection, stronger assistance capabilities and more integrated travel solutions that support travelers throughout their journeys. Travel protection has become a standard expectation Singapore ranks highest globally for travel insurance and protection coverage, with 86% of travelers covered when traveling and more than half (51%) intending to continue subscribing to travel insurance in the future. This market maturity is reflected in the types of risks Singaporeans choose to protect against, including loss of personal belongings, transportation accidents and health-related incidents, suggesting that travelers increasingly value comprehensive protection that extends beyond basic policy coverage. Singaporeans also remain among the world’s highest-spending travelers, with an average leisure holiday budget of USD 2,818. Yet affordability and company reputation remain important purchasing considerations when selecting travel protection, indicating that consumers are willing to invest in coverage when it offers clear value, trusted service and meaningful benefits. Virginie Babinet, CEO Travel Insurance & Assistance – Redion Group, said, "Building on the record levels seen last year, the desire to travel remains strong and undiminished, despite tougher trade-offs and the cost of living remaining a top global concern. What is changing, however, is the travel landscape itself. Security considerations are weighing more heavily on destination choices, with decisions increasingly shaped by risk considerations. At the same time, artificial intelligence is now a genuine planning tool for a growing number of travelers worldwide, as demonstrated by the distinct jump in numbers, particularly in emerging and high growth markets." Hassen Bennour, CEO of Redion Asia Pacific, said, “Singapore continues to set the pace for travel protection in the region, with 86% of travelers already covered, among the highest levels in the world. What is changing, however, is what travelers now expect this protection to deliver. Beyond coverage, Singaporeans want broader multi-risk protection, embedded assistance and reassurance that travels with them across every trip. At the same time, artificial intelligence is helping travelers plan faster, but confidence in the final decision still rests with human expertise. For insurers and industry partners, this is where the next opportunity lies: pairing digital speed with trusted human guidance to meet the standards of one of the most demanding travel markets globally." AI and digital tools help Singaporeans travel smarter, but human control still leads Singapore's strong digital adoption is also reshaping how travellers research, plan and manage their journeys. Nearly half (45%) of Singaporeans have used AI in holiday planning or booking, primarily to research destinations, compare travel options and build itineraries. A similar proportion (48%) would consider allowing AI to make bookings on their behalf, provided they retain the ability to review and approve decisions before purchase. The same trend is emerging in travel insurance. While the use of AI to compare travel insurance products remains relatively limited today, many travelers (47%) expect to rely on it more in the future because of the convenience and speed it offers. Interest is also growing in digital services that complement insurance policies, including emergency assistance, 24/7 customer support, real-time alerts, mobile access and digital claims services. The implication is evident that AI is preferred as a tool in the planning process, but decision-making and the trust that comes with it still needs a human checkpoint built into the journey. Rather than replacing human involvement, the findings suggest that travelers want digital convenience supported by visible human oversight, combining the speed of technology with the confidence of expert guidance. Frequent outbound and experience-driven travelers expect reassurance throughout the journey Singaporeans remain among the region’s most active travelers. More than 9 in 10 take at least one leisure trip annually, while the majority (84%) intend to travel internationally, despite persisting geopolitical uncertainty. Travel is increasingly experience-driven, with nearly 7 in 10 preferring city destinations, citing relaxation, exploration and local food and cultural discovery among their key motivations. Combined with high travel spending, these behaviors reflect a market that increasingly prioritizes quality experiences alongside value. As travellers invest more in their trips, expectations around protection and support naturally rise. The research found that concerns around natural disasters, epidemic outbreaks, terrorism and travel disruptions continue to influence travel decisions. Rather than discouraging travel, these concerns are driving demand for greater reassurance, flexibility and support before, during and after each journey. This creates opportunities for insurers and travel providers to embed safety, assistance and peace of mind into the overall customer journey as enablers of worry-free travel experiences. With most travelers taking their longest trips during the year-end period, particularly in November and December, the final quarter remains a critical window for travel providers to engage consumers through premium offerings, bundled experiences and integrated protection solutions. As expectations around travel continue to evolve, Singapore's world-leading level of protection coverage underscores a broader shift in how travellers view insurance and assistance. Increasingly, travellers are seeking protection that delivers peace of mind throughout the entire journey, supported by digital convenience, responsive assistance and trusted expertise whenever they need it. About Redion (formerly Europ Assistance) Redion is a world leader in assistance, travel insurance and employee benefits. The name, revealed in 2026, reflects the full maturity of the global Care platform that has been operating under Generali Care, bringing together Europ Assistance and Generali Employee Benefits (GEB). Operating in more than 190 countries, with over 12,000 employees and €5.8 billion in annual business volume, Redion delivers services spanning travel insurance, emergency and medical assistance, employee protection (life, disability, accident, medical), health and mobility solutions, as well as global B2B2C and embedded insurance programmes. Within its employee benefits offering, Redion builds on a global network of 224 active partners to provide multinational clients with protection, health, pension and wellbeing solutions across markets, combining global scale, local expertise and deep technical capabilities. For media enquiries, please contact: Benedict Gerald Rozario, Marketing & Communication, Redion East Asia M: +60-12 979 7238 E: [email protected] Nadzwan Tahir, Senior Executive Narro Communications M: +60-18 399 1646 E: [email protected]
- Luxshare Precision Reports 40.2% Revenue Growth in First Half 2026; Business Mix Supports Margin ExpansionCompanies: LuxshareBroad-based growth across consumer electronics, communications and data center, and automotive electronics, supported by targeted investment in AI infrastructure, intelligent vehicles and global delivery capacity DONGGUAN, China, Aug. 28, 2026 -- Luxshare Precision Industry...
- DigitalBridgeDigitalBridge to Acquire PLUS ES, a Leading Australian Smart Metering PlatformBOCA RATON, Fla., August 27, 2026--DigitalBridge, a leading global alternative asset manager dedicated to investing in digital infrastructure, today announced that a DigitalBridge-managed investment vehicle has entered into an agreement to acquire PLUS ES, one of Australia’s largest smart meter providers. PLUS ES is a separate ring-fenced entity within the Ausgrid Group. PLUS ES provides infrastructure and services that connect retailers, utilities and network operators with the data needed to m
- Stoneridge, Inc.Stoneridge Appoints Vivek Anand as Vice President, Commercial Strategy & Global SalesStoneridge, Inc. (NYSE: SRI), a global leader of safe, intelligent and efficient electronic technologies for the commercial vehicle and off-highway equipment markets, today announced the appointment of Vivek Anand as Vice President, Commercial...
- Automotive Finco Corp. Files Condensed Interim Consolidated Financial Statements for the Six Months ended June 30, 2026Not for distribution to United States newswire services or for dissemination in the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States.
- Chicago Automobile Trade AssociationChicagoland New-Car Dealers Raise More Than $59,000 for the USO in the 13th Annual Drive for the Troops CampaignThe Chicago Automobile Trade Association (CATA), in partnership with the USO, has concluded the 13th annual Drive for the Troops campaign, raising more than $59,000 to support service members and their families. Throughout the month of July,...
- The American Cancer Society Relay For LifeAmerican Cancer Society Announces 2026 Relay For Life of Conejo ValleyFundraising Event Held at California Lutheran University Kicks Off with a Non-Competitive 5.0K Fun Run and Features Competitive Car Show for the First Time — The American Cancer Society will introduce the 2026 Relay For Life of Conejo...
- Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New OpportunitiesCanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million, up 43.8% year on year, while its net loss attributable to shareholders narrowed significantly. Notably, while demand in China’s vaccine market remains challenging, CanSinoBIO’s international business maintained strong growth momentum, generating overseas revenue of RMB 150 million during the reporting period. As established products accelerate their expansion into overseas markets, and collaboration models such as technology partnerships and localized industrialization continue to take shape, CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance. This reflects the Company’s forward-looking understanding of global vaccine market trends and evolving demand in international markets. At a time when the vaccine industry is facing changes in demand structure, the combination of domestic innovation capabilities and access to international markets is becoming an increasingly important measure of corporate growth resilience. Overseas Growth Accelerates In the first half of 2026, China’s vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible. “Volume contraction and price decline” has emerged as a widespread challenge across the industry. Based on disclosed financial results across the sector, this pressure appears to be industry-wide. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year on year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year on year; despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine, revenue remained under pressure. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year on year. Against this industry backdrop, the growth of CanSinoBIO’s international business is particularly noteworthy. The Company reported overseas revenue of RMB 150 million in the first half of 2026. This growth was driven, on the one hand, by the continued expansion of mature products into overseas markets and, on the other, by the further deepening of the Company’s international partnership models. For CanSinoBIO, this also means that its products, manufacturing processes and quality control capabilities, validated in the domestic market, are beginning to unlock value overseas through more diversified approaches. Meanwhile, the Company continues to advance its international market footprint. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East. Menhycia(R) has obtained registration approvals in Indonesia and Argentina, and product supply has already commenced in Indonesia. As more products progress through overseas registration and commercialization, CanSinoBIO’s international business is expected to develop more diversified revenue streams and further strengthen its commercial resilience. From this perspective, CanSinoBIO’s globalization strategy is evolving. Overseas markets are no longer merely destinations for mature products, but are increasingly becoming markets in which products, technologies and industrial capabilities can jointly create value. For an innovative vaccine company, this shift from “exporting products” to “exporting capabilities and systems” creates greater room for long-term growth in its overseas business. Portfolio Upgrades Strengthen the Commercial Foundation Sustained overseas expansion is underpinned by a stable product portfolio and strong technological capabilities. According to the Company’s interim report, domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia(R), China’s first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population. Meanwhile, iPneucia(R), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia(R) has continued to expand market access and is now available in nearly 30 provincial-level markets across China. From meningococcal disease to pneumococcal disease, CanSinoBIO is using innovative products to address vaccine segments that continue to offer meaningful unmet demand. As traditional vaccine categories face pressure on volumes, structural growth driven by product and technology upgrades is providing important support for the Company’s commercial resilience. More importantly, the product-development and industrialization capabilities established in the domestic market also provide a foundation for overseas expansion. For an innovative vaccine company, successful commercialization in China not only broadens revenue sources, but also validates the manufacturing, quality-control and supply systems required to replicate and extend those capabilities into international markets. Domestic product upgrades and overseas business growth are thereforeclosely connected rather than separate. The former provides the foundation in products and technologies, while the latter expands the geographic boundaries within which those products can realize their value. Multi-Layered Pipeline Takes Shape to Support Future Growth For an innovative vaccine company, long-term growth depends not only on the commercial performance of existing products, but also on the ability to maintain a steady flow of new products. By pursuing continued ramp-up of marketed products, advancing products under regulatory review and developing next-generation candidates, CanSinoBIO is building a more sustainable and well-sequenced product pipeline. Tripecia(R) (DT3cP Infant), CanSinoBIO’s three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products. Provincial tendering and market-access processes are progressing in an orderly manner, and the product has begun entering the market supply stage. While Tripecia(R) represents an upgrade in pertussis vaccination for infants, the Td5cp vaccine for adolescents and adults — which has also been granted Priority Review status — is expected to extend CanSinoBIO’s pertussis vaccine portfolio to a broader population. The New Drug Application for Td5cp has been accepted by China’s National Medical Products Administration (NMPA). In addition, CanSinoBIO’s independently developed Adsorbed Tetanus Vaccine, Tetcia(R), has been formally approved, further strengthening the Company’s adult vaccine portfolio. From infants to adolescents and adults, and from individual products to a multi-product portfolio, this strategy is broadening the foundation for future commercial growth. In pneumococcal vaccines, CanSinoBIO’s 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, and participant enrollment across different cohorts is progressing as planned. At the same time, the Company continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats. Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The Company is conducting early-stage research into mRNA applications for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR therapies. These programs remain at an early stage, with the Company continuing to assess the potential of mRNA and related technologies in disease treatment. Additionally, on August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines. These pipeline programs represent extensions of CanSinoBIO’s existing technology platforms and product-development experience. The Company’s core platforms — including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, as well as formulation and delivery technologies — provide a foundation for continued product iteration and technology translation. Innovation Supports Long-Term Development Viewed in the context of its 2026 interim results, CanSinoBIO’s story is not simply one of revenue growth. Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. Overseas business model expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth. At the same time, Tripecia(R) has entered the market supply stage, the Td5cp vaccine for adolescents and adults is progressing through regulatory review, and pipeline programs including PCV24, multivalent and combination vaccines, and mRNA technologies continue to advance, providing both product succession and technology reserves for the future. These three pathways ultimately point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term. In an environment where demand for traditional vaccines is under pressure and industry competition is intensifying, growth is increasingly shifting away from reliance on product-volume expansion alone and toward a model jointly driven by product upgrades, technological innovation and global markets. For CanSinoBIO, continued growth in the overseas business is providing increasingly visible financial evidence of this transition. As more innovative products enter the market, more mature products expand overseas and the Company’s technical capabilities extend further into international value chains, CanSinoBIO’s growth runway is expanding from a single domestic market to the global market. For the Company, internationalization is not only about broadening geographic reach; it is also an important pathway for innovative products and technologies to realize greater commercial value while contributing to global public health.
- Global Transparent Displays Market to Reach $8.7 Billion by 2030, Driven by Rising Adoption of Digital Signage and HUD Solutions Across Automotive, Retail, and Smart InfrastructureBCC Research LLC 50 Milk St., Ste. 16, Boston, MA 02109 [email protected] | +1 781-489-7301 www.bccresearch.com
- Nexteer; Phoenix InvestorsPHOENIX INVESTORS AND NEXTEER AUTOMOTIVE ANNOUNCE COMPLETION OF 1.8 MILLION-SQUARE-FOOT, THREE-BUILDING INDUSTRIAL PROPERTY TRANSACTION IN SAGINAW, MICHIGANAcquisition supports Nexteer's continued manufacturing operations while creating significant new investment, redevelopment, and leasing opportunities in Buena Vista Charter Township — An affiliate of Milwaukee-based Phoenix Investors...